Apimeds Pharmaceuticals U... (APUS)
NYSE: APUS
· Real-Time Price · USD
1.97
0.16 (8.84%)
At close: Aug 21, 2025, 10:02 AM
Apimeds Pharmaceuticals US Inc Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -364.37K | -275.61K | -300K | -427.76K | -271.73K | -559.07K | -104.16K | -27.83K | -56.38K | -66.19K |
Interest Income | 3.00 | 30.00 | 116.00 | 517.00 | 2.16K | 5.58K | 2.23K | n/a | n/a | n/a |
Pretax Income | -402.4K | -311.63K | -332.52K | -449.36K | -296.47K | -566.97K | -110.02K | -36.08K | -64.63K | -74.59K |
Net Income | -402.4K | -311.63K | -332.52K | -449.36K | -296.47K | -566.97K | -110.02K | -36.08K | -64.63K | -74.59K |
Selling & General & Admin | 364.37K | 275.61K | 300K | 427.76K | 271.73K | 530.52K | 107.16K | 5.38K | 5.83K | 4.07K |
Research & Development | n/a | n/a | n/a | n/a | n/a | 28.55K | -3K | 22.44K | 50.55K | 62.12K |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 364.37K | 275.61K | 300K | 427.76K | 271.73K | 559.07K | 104.16K | 27.83K | 56.38K | 66.19K |
Interest Expense | 38.03K | 36.05K | 32.64K | 22.12K | 26.91K | 13.48K | 8.09K | 8.25K | 8.25K | 8.41K |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 364.37K | 275.61K | 300K | 427.76K | 271.73K | 559.07K | 104.16K | 27.83K | 56.38K | 66.19K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 11.57M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M | 11.53M |
Shares Outstanding (Diluted) | 11.57M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M | 12.69M |
EPS (Basic) | -0.03 | -0.03 | -0.03 | -0.04 | -0.03 | -0.05 | -0.01 | -0.00 | -0.01 | -0.01 |
EPS (Diluted) | -0.03 | -0.02 | -0.03 | -0.04 | -0.02 | -0.04 | -0.01 | -0.00 | -0.01 | -0.01 |
EBITDA | -364.37K | -275.58K | -299.88K | -427.24K | -269.56K | -553.49K | -101.93K | -27.83K | -56.38K | -66.19K |
EBIT | -364.37K | -275.58K | -299.88K | -427.24K | -269.56K | -553.49K | -101.93K | -27.83K | -56.38K | -66.19K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |